


# PRODUCT INFORMATION



**BI-1467335**

Item No. 30672

**CAS Registry No.:** 1478364-68-9  
**Formal Name:** 4-[[[(2E)-2-(aminomethyl)-3-fluoro-2-propen-1-yl]oxy]-N-(1,1-dimethylethyl)-benzamide, monohydrochloride  
**Synonym:** PXS-4728A  
**MF:** C<sub>15</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>2</sub> • HCl  
**FW:** 316.8  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

BI-1467335 is supplied as a solid. A stock solution may be made by dissolving the BI-1467335 in the solvent of choice, which should be purged with an inert gas. BI-1467335 is soluble in organic solvents such as DMSO. It is also soluble in water. We do not recommend storing the aqueous solution for more than one day.

## Description

BI-1467335 is an inhibitor of vascular adhesion protein-1 (VAP-1; IC<sub>50</sub> = <100 nM), also known as semicarbazide-sensitive amine oxidase (SSAO), an enzyme with roles in leukocyte adhesion and transmigration.<sup>1</sup> It is selective for VAP-1 over monoamine oxidase B (MAO-B) and diamine oxidase (DAO; IC<sub>50</sub>s = >1,000 and >10,000 nM, respectively). Oral administration of BI-1467335 (10 mg/kg per day) reduces plasma total cholesterol, LDL, and glucose levels, as well as decreases the recruitment of macrophages to atherosclerotic lesions and the area of atherosclerotic plaques, in a cholesterol-fed rabbit model.<sup>2</sup> It reduces neutrophil lung infiltration induced by *K. pneumoniae* in mice when administered at a dose of 6 mg/kg.<sup>3</sup> It also reduces airway hyperreactivity in a mouse model of rhinovirus-exacerbated allergy-induced asthma.

## References

1. Deodhar, M., Findlay, A.D., Foot, J.S., *et al.* Substituted 3-haloallylamine inhibitors of SSAO and uses thereof. *Pharmaxis, Ltd. WO 2013/163675 A1* (2020).
2. Wang, S.-H., Yu, T.-Y., Hung, C.-S., *et al.* Inhibition of semicarbazide-sensitive amine oxidase reduces atherosclerosis in cholesterol-fed New Zealand white rabbits. *Sci. Rep.* **8(1)**, 9249 (2018).
3. Schilter, H.C., Collison, A., Russo, R.C., *et al.* Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. *Respir. Res.* **16(1)**, 42 (2018).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/26/2024

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM